Grace Therapeutics, Inc.
GTx-104
aneurysmal subarachnoid hemorrhage (aSAH)
Resolved
75days ago
FDA decision · Apr 23, 2026
What's at stake
An FDA complete response letter on GTx-104 for aneurysmal subarachnoid hemorrhage (aSAH) is in focus around Apr 23, 2026.
Primary source
· SEC 8-K
verified 15h ago
“On April 23, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company’s New Drug Application for GTx-104 in the treatme”